Selected article for: "critical illness and potential benefit"

Author: Al-Samkari, Hanny; Karp Leaf, Rebecca S.; Dzik, Walter H.; Carlson, Jonathan C.T.; Fogerty, Annemarie E.; Waheed, Anem; Goodarzi, Katayoon; Bendapudi, Pavan K.; Bornikova, Larissa; Gupta, Shruti; Leaf, David E.; Kuter, David J.; Rosovsky, Rachel P.
Title: COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
  • Cord-id: it6qad4p
  • Document date: 2020_7_23
  • ID: it6qad4p
    Snippet: Abstract Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited. This multicenter retrospective study describes the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation and inflammatory paramet
    Document: Abstract Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early reports describe high venous thromboembolism (VTE) and disseminated intravascular coagulation (DIC) rates, but data are limited. This multicenter retrospective study describes the rate and severity of hemostatic and thrombotic complications of 400 hospital-admitted COVID-19 patients (144 critically ill) primarily receiving standard-dose prophylactic anticoagulation. Coagulation and inflammatory parameters were compared between patients with and without coagulation-associated complications. Multivariable logistic models examined the utility of these markers in predicting coagulation-associated complications, critical illness, and death. The radiographically confirmed VTE rate was 4.8% (95% confidence interval [CI], 2.9-7.3), and the overall thrombotic complication rate was 9.5% (95% CI, 6.8-12.8). The overall and major bleeding rates were 4.8% (95% CI, 2.9-7.3) and 2.3% (95% CI, 1.0-4.2), respectively. In the critically ill, radiographically confirmed VTE and major bleeding rates were 7.6% (95% CI, 3.9-13.3) and 5.6% (95% CI, 2.4-10.7), respectively. Elevated D-dimer at initial presentation was predictive of coagulation-associated complications during hospitalization (D-dimer >2500 ng/mL, adjusted odds ratio [OR] for thrombosis, 6.79 [95% CI, 2.39-19.30]; adjusted OR for bleeding, 3.56 [95% CI, 1.01-12.66]), critical illness, and death. Additional markers at initial presentation predictive of thrombosis during hospitalization included platelet count >450 × 109/L (adjusted OR, 3.56 [95% CI, 1.27-9.97]), C-reactive protein (CRP) >100 mg/L (adjusted OR, 2.71 [95% CI, 1.26-5.86]), and erythrocyte sedimentation rate (ESR) >40 mm/h (adjusted OR, 2.64 [95% CI, 1.07-6.51]). ESR, CRP, fibrinogen, ferritin, and procalcitonin were higher in patients with thrombotic complications than in those without. DIC, clinically relevant thrombocytopenia, and reduced fibrinogen were rare and were associated with significant bleeding manifestations. Given the observed bleeding rates, randomized trials are needed to determine any potential benefit of intensified anticoagulant prophylaxis in COVID-19 patients.

    Search related documents:
    Co phrase search for related documents
    • abnormal coagulation and admission dimer: 1, 2, 3, 4
    • abnormal coagulation and lmwh weight heparin: 1, 2, 3
    • abnormal coagulation and low molecular lmwh weight heparin: 1, 2, 3
    • abnormal coagulation and lung disease: 1, 2
    • abnormal coagulation testing and lung disease: 1
    • acute inflammation and admission dimer: 1
    • acute inflammation and lmwh weight heparin: 1
    • acute inflammation and long term care facility: 1
    • acute inflammation and low molecular lmwh weight heparin: 1
    • acute inflammation and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
    • admission dimer and lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
    • admission dimer and logistic regression model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • admission dimer and long term care facility: 1
    • admission dimer and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7
    • admission dimer and lung disease: 1, 2, 3, 4, 5
    • liver cirrhosis and logistic regression model: 1, 2
    • liver cirrhosis and lung disease: 1, 2, 3, 4
    • lmwh weight heparin and low molecular lmwh weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • lmwh weight heparin and lung disease: 1